Abstract
Biological markers can be used to identify the neurodegenerative process of Alzheimer’s disease (AD) and to differentiate it from other brain diseases which may cause similar symptoms. Structural imaging can detect atrophic changes which are largely non-specific and provide little diagnostic information in single patients. Increasing atrophy upon repeated measurement is much more specific to AD. Functional imaging can demonstrate regional alterations of cerebral blood flow and metabolism but is not sufficiently sensitive at the stage of mild dementia. The measurement of neuronal proteins in the cerebrospinal fluid including tau, phospho-tau, and Bamyloid, achieve high diagnostic sensitivity and specificity even at the stage of pre-dementia. Genetic tests for mutations in the amyloid precursor and presenilin genes are applicable in very few cases. Apolipoprotein E genotyping is not useful as a diagnostic test. With respect to the limitations of biological markers clinical expertise will continue to be an essential element of the early and differential diagnosis of AD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
American College of Medical Genetics (1995) Consensus statement: statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 274: 1627–1629
Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K (1999) Cerebrospinal fluid tau and A ß 42 as predictors of development of Alzheimer’s disease in patients with mild cognitive impairment. Neurosci Lett 273: 5–8
Arai H, Ishiguro K, Ohno H, Moriyama M, Hoh N, Okamura N, Matsui T, Morikawa Y, Horikawa E, Kohno H, et al (2000) CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol166: 201–203
Bartres-Faz D, Junque C, Lpez-Alomar A, Velveny N, Moral P, Casamayor R, Salido A, Bel C, Clemente IC (2001) Neuropsychological and genetic differences between ageassociated memory impairment and mild cognitive impairment entities. JAm Geriatr Soc 49: 985–990
Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol Scand [Suppl] 165: 3–12
Catani M, Cherubini A, Howard R, Tarducci R, Pellicciolo CP, Piccirilli M, Gobbi G, Senin U, Mecocci P (2001) (l)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 12: 2315–2317
De Leon MJ, George AE, Golomb J, Tarshish S, Convit A, Kluger A, De-Santi S, McRae T, Ferris SH, Reisberg B, et al (1997) Frequency of hippocampal formation atrophy in normal aging and Alzheimer’s disease. Neurobiol Aging 18: 1–11
De Santi S, de Leon MH, Rusinek H, Convit A, Tashish CY, Roche A, Tsui WH, Kandil E, Boppana M, Daisley K, et al (2001) Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22: 529–539
Fox NC, Warrington EK, Stevens JM, Rossor MN (1996) Atrophy of the hippocampal formation in early familial Alzheimer’s disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717 Val-Gly mutation. Ann NY Acad Sci 777: 226–232
Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, et al (1998) High cerebrospinal fluid tau and low amyloid ß 42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55: 937–945
Gonzalez RG, Guimaraes AR, Moore GJ, Crawley A, Cupples LA, Growdon JH (1996) Quantiative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease. Alzheimer Dis Assoc Disord 10: 46–52
Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, DeDeyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, et al (1999) Improved discrimination of AD patients using ß-amyloid(l--42) and tau levels in CSF. Neurology 52: 15551562
Jack CR, Petersen RC, Xu YC, Waring SC, O’Brien PC, Tangalos EG, Smith GE, Ivnik RJ, Kokmen E (1997) Medial temporal atrophy in normal aging and very mild Alzheimer’s disease. Neurology 49: 786–794 Biological markers and AD 133
Jelic V, Nordberg A (2000) Early diagnosis of Alzheimer disease with positron emission tomography. Alzheimer Dis Assoc Disord 14: S109–113
Jessen F, Block W, Traber F, Keller E, Placke S, Papassotiropoulos A, Lamerichs R, Heun R, Schild HH (2000) Proton MR spectroscopy detects a relative decrease of Nacetylaspartate in the medial temporal lobe of patients with AD. Neurology 55: 684688
Kantarci K, Jack CR, Xu YC, Campeau NG, O’Brien PC, Smith GE, Ivnik RJ, Boeve BF, Kokmen E, Tangalos EG, et al (2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease: a 1H MRS study. Neurology 55: 210–217
Laakso MP, Partanen K, Riekkinen P, Lehtovirta M, Helkala EL, Hallikainen M, Hiinninen T, Vainio P, Soininen H (1996) Hippocampal volumes in Alzheimer’s disease, Parkinson’s disease with and without dementia, and in vascular dementia: an MRI study. Neurology 46: 678–681
Lautenschlager NT, Riemenschneider M, Drzezga A, Kurz AF (20Gl) Primary degenerative mild cognitive impairment: study population, clinical, brain imaging, and biochemical findings. Dement Geriatr Cogn Disord 12: 379–386
Linn RT, Wolf PA, Bachman DL, Knoefel IE, Cobb JL, Belanger AI Kaplan EF, D’Agostino RB (1995) The ’preclinical phase’ of probable Alzheimer’s disease. A 13year prospective study of the Framingham cohort. Arch Neurol 52: 485–490
Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, et al (2001) Cerebrospinal fluid amyloid beta(1–42) levels in mild cognitive impairment stage of Alzheimer’s disease. Exp Neurol l72: 433–436
Matsuda H (2001) Cerebral blood flow and metabolic abnormalities in Alzheimer’s disease. Ann Nucl Med 15: 85–92
Petersen RC (1995) Normal aging, mild cognitive impairment, and early Alzheimer’s disease. Neurologist 1: 326–344
Rasmusson DX, Brandt J, Steele C, Hedreen JC, Troncoso JC, Folstein MF (1996) Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer Dis Assoc Disord 10: 180188
Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG (1997) Diagnosis of Alzheimer’s disease with cerebrospinal fluid tau protein and aspartate aminotransferase. Lancet 350: 784
Scheltens P, Karf ES (2000) Contribution of neuroimaging in the diagnosis of Alzheimer’s disease and other dementias. CUff Opin Neurol13: 391–396
Smith AD, Jobst KA (1996) Use of structural imaging to study the progression of Alzheimer’s disease. Br Med Bull 52: 575–586
Terajima M, Arai H, Higuchi M, Zhu C, Sasaki H (1996) Elevated cerebrospinal fluid tau: Implications for early diagnosis of Alzheimer’s disase. J Am Geriatr Soc 44: 10121013
Valenzuela MI, Sachdev P (2001) Magnetic resonance spectroscopy in AD. Neuroloy 56: 592–598
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Wien
About this paper
Cite this paper
Kurz, A., Riemenschneider, M., Drzezga, A., Lautenschlager, N. (2002). The role of biological markers in the early and differential diagnosis of Alzheimer’s disease. In: Jellinger, K.A., Schmidt, R., Windisch, M. (eds) Ageing and Dementia Current and Future Concepts. Journal of Neural Transmission. Supplementa, vol 62. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6139-5_13
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6139-5_13
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83796-2
Online ISBN: 978-3-7091-6139-5
eBook Packages: Springer Book Archive